{"id":17596,"date":"2015-12-18T17:09:00","date_gmt":"2015-12-18T14:09:00","guid":{"rendered":"http:\/\/en.ldaily.ua\/?p=17596"},"modified":"2015-12-18T18:34:38","modified_gmt":"2015-12-18T15:34:38","slug":"astrazeneka-global-pharmaceutical-company-merges-with-acepta-pharma","status":"publish","type":"news","link":"https:\/\/ldaily.ua\/en\/news\/astrazeneka-global-pharmaceutical-company-merges-with-acepta-pharma\/","title":{"rendered":"AstraZeneca global pharmaceutical company merges with Acepta Pharma"},"content":{"rendered":"<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-17589 size-medium\" src=\"https:\/\/ldaily.ua\/wp-content\/uploads\/2015\/12\/Astra-zeneca-320x180.jpg\" alt=\"AstraZeneka global pharmaceutical company merges with Acepta Pharma\" width=\"320\" height=\"180\" title=\"\"><em>On Thursday, the British drugmaker AstraZeneca said it agreed to buy a controlling stake in the biotech company Acerta Pharma for $ 4 billion.<\/em><\/p>\n<p style=\"text-align: justify;\">Analysts point out that the operations that were carried out in the health sector helped to make 2015 a record year for mergers and acquisitions.<\/p>\n<p style=\"text-align: justify;\">In the legal field, the merger is profitable for pharmaceutical companies. They are used to optimize production, to unite the efforts to develop new products.<\/p>\n<p style=\"text-align: justify;\">Buying Acepta Pharma will help AstraZeneca to strengthen and develop the production of drugs for the treatment of cancer at a later stage, said in an interview the executive director of AstraZeneca Pascal Soriot.<\/p>\n<p style=\"text-align: justify;\">In accordance with the terms of the deal, AstraZeneca will acquire 55% stake in the Acerta. The initial payment will be paid in the amount of $ 2.5 billion. The remaining $ 1.5 billion the company will pay in 2018, or upon approval by the US regulatory authorities akalabrutinib drug that is intended for the treatment of cancer pathology.<\/p>\n<p style=\"text-align: justify;\">Experts predict that if the drug is approved by regulators, the annual amount of its sales could reach $ 5 billion.<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00abAstraZeneca\u00bb can buy the remaining shares \u00abAcerta Pharma\u00bb for $ 3 billion, but it will happen after akalabrutinib get a license in the United States and Europe. And the purchase of a full package of shares would be effected in the case if the drug is successfully implemented.<\/p>\n<p style=\"text-align: justify;\"><em>The AstraZeneca has big plans aimed at merging. In November, it agreed to buy California biopharmaceutical company ZS Pharma for $ 2.7 billion in cash. This week, AstraZeneca also announced that it would buy the Japanese Takeda Pharmaceutical Company of Japan for $ 575 million.<\/em><\/p>\n<p style=\"text-align: justify;\">Source: www.nytimes.com<\/p>\n","protected":false},"featured_media":17590,"menu_order":0,"template":"","newscat":[9],"newstag":[],"issues":[],"class_list":["post-17596","news","type-news","status-publish","has-post-thumbnail","hentry","newscat-novosti"],"_links":{"self":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news\/17596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media\/17590"}],"wp:attachment":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media?parent=17596"}],"wp:term":[{"taxonomy":"newscat","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newscat?post=17596"},{"taxonomy":"newstag","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newstag?post=17596"},{"taxonomy":"issues","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/issues?post=17596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}